SCHEMBL9924231

SCHEMBL9924231

CC(C)(C)c1ccccc1N/C(=N\C(=O)c1ccc(C(F)(F)F)cc1)N[C@H]1CC[C@H](O)CC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.41
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
TRPV1 Q8NER1 3/20 0.39
P2RY1 P47900 3/20 0.37
KDM4E B2RXH2 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
PTGS1 P23219 1/20 0.37
EPHX2 P34913 2/20 0.35
MRGPRX4 Q96LA9 1/20 0.35
BRD4 O60885 1/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPT P10636 1/20 0.35
ALOX12 P18054 1/20 0.35
DRD2 P14416 1/20 0.35
DRD4 P21917 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9924129 0.85 TRPV1 (0.39) MAPK11MAPK14TRPV1PTGS1EPHX2
SCHEMBL9924153 0.82 TRPV1 (0.42) MAPK11MAPK14TRPV1EPHX2MRGPRX4
SCHEMBL17206700 0.80 EPHX2 (0.47) TRPV1EPHX2
SCHEMBL9924227 0.79 EPHX2 (0.52) LMNAPTGS1EPHX2MAPT
SCHEMBL9924262 0.77 UBE2M (0.46) LMNATRPV1PTGS1EPHX2MRGPRX4
SCHEMBL9939759 0.74 P2RY1 (0.38) LMNATRPV1P2RY1KDM4EPTGS1
SCHEMBL19362654 0.74 TRPV1 (0.42) MAPK11MAPK14TRPV1EPHX2MRGPRX4
SCHEMBL9924261 0.74 TRPV1 (0.42) TRPV1EPHX2MRGPRX4ALDH1A1
SCHEMBL17206709 0.74 TRPV1 (0.42) TRPV1EPHX2MRGPRX4ALDH1A1
SCHEMBL17206621 0.74 EPHX2 (0.43) KDM4ETDP1EPHX2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9169199-B2 Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof LYCERA CORPORATION (US) 2015-10-27 US disclosed
WO-2012078867-A2 CYCLOALKYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF LYCERA CORPORATION (US) 2012-06-14 WO disclosed